Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers
The current study offers RWE to suggest similar outcomes with innovator and generic bevacizumab when combined with chemotherapy in mCRCs. This has significant implications in India and other low- and middle-income countries besides providing oncologists with greater confidence to use these molecules in their clinical practice.
Authors
- Prabhat Bhargava (ORCID: https://orcid.org/0000-0002-6440-2186)
- Pranaya Vana
- Nachiket Joshi (ORCID: https://orcid.org/0000-0003-1503-5006)
- Anant Ramaswamy (ORCID: https://orcid.org/0000-0002-8169-4264)
- Arvind Vaidyanathan
- Vikas S Ostwal (ORCID: https://orcid.org/0000-0002-0067-4748)
- George John (ORCID: https://orcid.org/0000-0001-6145-1591)
- Bikash Sourav
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
Publication Details
- Journal
- South Asian Journal of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1055/s-0045-1804535
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28